Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health (ELAN) delivers innovative health solutions for pets and livestock worldwide. This dedicated news hub provides investors and industry professionals with essential updates on corporate developments, product innovations, and strategic initiatives shaping the animal health sector.
Access real-time press releases, earnings announcements, and regulatory filings alongside analysis of ELAN's advancements in veterinary pharmaceuticals. Our curated collection simplifies tracking of:
- Quarterly financial results and investor communications
- New product launches and FDA approvals
- Strategic partnerships and R&D milestones
- Industry leadership initiatives and sustainability efforts
Bookmark this page for streamlined access to verified ELAN updates. Combine our news feed with SEC filings and market analysis tools for comprehensive due diligence in the dynamic animal health market.
Elanco Animal Health (NYSE: ELAN) responded to a U.S. House subcommittee request regarding misleading media claims about Seresto collars. The company reaffirms the safety and efficacy of Seresto, stating no recall is warranted. Over 25 million collars have been sold since 2012 with an adverse event rate below 0.3%, primarily non-serious. Elanco collaborates with the subcommittee and emphasizes the lack of scientific basis for a recall. The company underscores its commitment to product safety and continuous monitoring of health data.
Morris Animal Foundation is collaborating with Elanco Animal Health (NYSE: ELAN) to investigate osteoarthritis (OA) in dogs through data from the Golden Retriever Lifetime Study. This study highlights that approximately 14 million adult dogs in the U.S. suffer from OA, often diagnosed in their senior years. Elanco will enhance questionnaires to evaluate OA signs, including walking gait and joint range of motion. The Golden Retriever Lifetime Study is a significant research initiative involving over 3,000 dogs to assess health factors contributing to diseases, including cancer.
Elanco Animal Health Incorporated (NYSE: ELAN) reported its Q4 and full year 2020 financial results, exceeding guidance due to strong performance in U.S. Pet Health and Farm Animal sectors. Revenue reached $1,140 million, surpassing the $1,040 - $1,070 million guidance. Adjusted EPS met expectations, reflecting ongoing productivity efforts. Elanco is optimistic about 2021, raising guidance based on its Innovation, Portfolio, Productivity strategy and solid fundamentals. The company is focused on capturing synergies from the Bayer Animal Health acquisition, enhancing its market position.
Elanco Animal Health (NYSE: ELAN) announced the departure of executive vice president Michael-Bryant Hicks on March 2. Hicks played a crucial role since 2018 in guiding the company through its IPO and the acquisition of Bayer Animal Health. CEO Jeff Simmons expressed gratitude for Hicks' contributions, emphasizing his unique skill set in transforming Elanco into a standalone entity. Hicks plans to leverage his experience in future leadership roles. The company is currently in the process of finding a replacement for Hicks.
Elanco Animal Health (NYSE: ELAN) has announced significant innovation milestones, including two crucial product approvals. The U.S. FDA approved Increxxa™ for treating bovine and swine respiratory diseases, while Health Canada approved Experior™ 50, the first animal health product aimed at reducing ammonia emissions. In Europe, positive progress was made for Credelio Plus Chewable tablets, and Credelio CAT is expected to receive FDA approval soon. These advancements are expected to drive Elanco's growth, with an anticipated $500-$600 million in new product revenues by 2025.
Elanco Animal Health (NYSE: ELAN) will participate in the Cowen 41st Annual Health Care Conference on March 2, 2021, at 2:50 p.m. ET. Jeff Simmons, the president and CEO, will engage in a virtual fireside chat. A live audio webcast will be available on Elanco's investor website, with replay access for 90 days. Elanco is dedicated to innovating products for the health of animals, following a mission of Food and Companionship Enriching Life.
Elanco Animal Health (NYSE: ELAN) will participate in the BofA Securities Animal Health Virtual Summit on February 25, 2021, featuring a fireside chat with CEO Jeff Simmons at 3:30 p.m. ET. A live audio webcast will be accessible on Elanco’s investor website, with a replay available for 90 days. Elanco is dedicated to innovating animal health products for farm animals and pets, supporting the health of animals, people, and the planet.
Elanco Animal Health (NYSE: ELAN) will release its fourth quarter 2020 financial results on February 24, 2021. A conference call will take place at 8:00 a.m. ET to discuss the results with investors, media, and the public. Participants can access the call via a live webcast on Elanco's website. Established nearly 70 years ago, Elanco is a global leader in animal health, focusing on innovating products and services for farm animals and pets, while promoting sustainability and improving animal health.
AgBiome has appointed Dr. Marijn Dekkers as Chairman of the Board, effective January 1, 2021. Dekkers, a former CEO of Bayer AG and Thermo Fisher Scientific, will leverage his extensive experience to guide AgBiome's growth strategies. Notably, AgBiome is focused on developing natural crop protection products through its proprietary GENESIS™ discovery platform, targeting a significant market opportunity valued at 100 billion dollars. The company also collaborates with Elanco Animal Health to create nutritional health solutions for swine.
Elanco Animal Health (NYSE: ELAN) announces that Sarena Lin, executive VP of Transformation and Technology, will leave the company at the end of January. Lin has played a crucial role in integrating Bayer's animal health business, achieving $300 million in synergies ahead of schedule. As Elanco progresses through its Innovation, Productivity, and Portfolio strategy, responsibility for finance and integration will shift to CFO Todd Young. The company anticipates eight product launches in 2021, with one potentially being a blockbuster, alongside targeted cost savings of $100 million.
